In fact, the SCD inhibitor YTX‐7739, which decreases the fatty acid desaturation index in rodents and monkeys,20 has now advanced to a phase 1 clinical trial for the treatment of PD (https://www.onderzoekmetmensen.nl/en/trial/20317). This evidence concerns the gene SCD and Parkinson disease.